Palexia (Tapentadol)

Tapentadol, the active ingredient in Palexia, is an opioid analgesic presented as a strength/form for oral use. It is indicated for the management of moderate to severe acute pain in adults. GNH USA supplies Palexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Palexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tapentadol is used in the management of pain through its action on the central nervous system.

- Acute postoperative pain: provides analgesia after surgical procedures. - Chronic musculoskeletal pain: helps control persistent pain from conditions such as osteoarthritis. - Cancer‑related pain: used as part of a multimodal regimen for malignant disease‑associated pain.

Tapentadol may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Nausea - Constipation - Dizziness - Somnolence - Headache - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - Seizures - Severe hypotension - Allergic reactions such as rash or angio‑edema - Serotonin syndrome (when combined with serotonergic agents) - Adrenal insufficiency

When using Palexia, several precautions should be considered to ensure safe and effective therapy.

- Assess pain severity: confirm that the pain level warrants opioid treatment. - Evaluate respiratory function: patients with compromised breathing need close monitoring. - Review medical history: consider prior opioid use, substance abuse, or psychiatric conditions. - Monitor for drug dependence: watch for signs of tolerance, misuse, or addiction. - Adjust for renal or hepatic impairment: dose may need modification in organ dysfunction. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Tapentadol can interact with several medication classes, influencing its safety and efficacy.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CNS depressants: increased risk of respiratory depression and sedation. - Serotonergic drugs: potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors: may alter tapentadol metabolism. - Diuretics: can enhance hypotensive effects. - Antihistamines: may increase sedation. - Alcohol: additive central nervous system depression.